The B12 injection frequency varies depending on the reason for treatment
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
it reflects standard peptide stability chemistry
In particular, we need to support our livers Phase II detoxification pathway to ensure toxins released from our bodys fat storage in Phase I are not released and recycled, adding to our livers already toxic load
Notably, experts reported that the use of oral semaglutide is associated with an enhanced sense of well-being and heightened performance, potentially contributing to better adherence to therapy regimens